Apogee Therapeutics (APGE) Current Leases (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Current Leases data on file, last reported at $3.1 million in Q1 2026.

• On a quarterly basis, Current Leases fell 22.5% year-over-year to $3.1 million in Q1 2026; TTM through Mar 2026 was $3.1 million, a 22.5% decrease from a year earlier, with the FY2025 full-year figure at $3.5 million, up 8.35% from the prior year.
• Current Leases for Q1 2026 stood at $3.1 million, down from $3.5 million in the prior quarter.
• Over the last five years, Current Leases for APGE reached as high as $4.1 million in Q3 2025 and fell as low as $1.1 million in Q4 2023.
• Historically, Current Leases has averaged $2.9 million across 4 years, with a median of $3.2 million in 2024.
• Across the five-year window, Current Leases surged 250.57% in 2025 and retreated 22.5% in 2026, its largest moves.
• Year by year, Current Leases stood at $1.1 million in 2023, then soared by 193.73% to $3.2 million in 2024, then rose by 8.35% to $3.5 million in 2025, then retreated by 11.53% to $3.1 million in 2026.
• Per Business Quant data, the three most recent Current Leases figures were $3.1 million in Q1 2026, $3.5 million in Q4 2025, and $4.1 million in Q3 2025.